Maroc approves two ‘Made in India’ oncology drugs

Indian pharmaceutical group “Venus Remedies Ltd” said on Monday, September 30, that the availability of these licenses was obtained from Marché Marocain for two specific oncology pharmaceuticals: carboplatin and bortezomib.

“These authorizations are essential to our strategy for cancer treatments. Nous sommes en passe de venir le premier fournisseur de produits oncologiques en Asia du Sud-Est,” Saransh Chaudhary, president of Global Critical Care at Venus Remedies, said in a statement.
In Maroc, the market for oncology drugs worth $150.8 million by 2029, the approval of carboplatin strengthens Venus Remedies’ position in the African oncology market.
Aditi K. Chaudhary, President of the international activities of the society, a declarant: “ These authorizations reflect the relative commitment to four solutions for innovative and affordable innovations and affordable. ». Venus Remedies, where the siege is located in Panchkula, India, has 15 authorizations in the Royaume.
Pour rappel, le ministère de la Santé et de la Protection sociale anonnce, en mai 2024, de nouvelles réductions de prix concernant plusieres Médicaments utilisés pour traiter les maladies cancéreuses et diabétiques And in biologically similar products no website is marketed.
The decision a été prize in accordance with Arrêté no.

The new text includes information on the revisions of public sale prices for original medicines, generics and biosimilars marketed in Maroc, according to decision no. 787.14.
According to the ministerial decree, the price reductions concern 29 medical compounds, with reductions ranging between 50 and 100 dirhams for low price medicines. For drugs plus costeux, reductions can range from 289 to 640 dirhams, voire plus, for public sale. For example, 30 grams of TAKROZEM ointment, used to treat skin inflammations in teenagers, will be sold publicly for 167 dirhams, compared to 104 dirhams for hospitals.